#1 Clinical Trials Search in Europe

Rasagiline

Rasagiline, a medication used in the treatment of Parkinson’s disease, has been the subject of numerous clinical trials to evaluate its effectiveness, safety, and potential benefits. These studies have explored various aspects of rasagiline’s use, including its impact on motor symptoms, cognitive function, sleep disturbances, and overall quality of life for patients with Parkinson’s disease. This article summarizes key findings from clinical trials investigating rasagiline, providing valuable insights into its potential as a treatment option for individuals living with this neurodegenerative disorder.

Table of Contents

What is Rasagiline?

Rasagiline is a medication primarily used to treat Parkinson’s disease. It’s also known by its brand names Azilect® and AZILECT®, and sometimes referred to as rasagiline mesylate or TVP1012[1][2]. This drug belongs to a class of medications called monoamine oxidase B (MAO-B) inhibitors, which work by increasing certain brain chemicals that are involved in movement control[1].

Uses of Rasagiline

Rasagiline is primarily used to treat Parkinson’s disease, a progressive nervous system disorder that affects movement. It can be used in different stages of the disease:

  • Early-stage Parkinson’s disease: Rasagiline may be used alone to help manage symptoms in the early stages of the disease[1].
  • Advanced Parkinson’s disease: It can be used in combination with levodopa (another Parkinson’s medication) to help manage motor fluctuations, also known as “wearing-off” symptoms[2][6].

In addition to its primary use, researchers are investigating rasagiline’s potential benefits for other conditions:

  • Sleep disturbances in Parkinson’s disease: Some studies are looking at how rasagiline might improve sleep problems that often accompany Parkinson’s disease[3].
  • Cognitive impairment in Parkinson’s disease: Researchers are exploring whether rasagiline could help improve thinking and memory problems associated with Parkinson’s disease[2].
  • Amyotrophic Lateral Sclerosis (ALS): Some research is investigating whether rasagiline might have potential benefits for people with ALS, also known as Lou Gehrig’s disease[10].

How Rasagiline Works

Rasagiline works by inhibiting an enzyme in the brain called monoamine oxidase B (MAO-B). This enzyme is responsible for breaking down dopamine, a crucial brain chemical involved in movement control. By inhibiting MAO-B, rasagiline helps to increase dopamine levels in the brain, which can improve motor symptoms of Parkinson’s disease[1].

Some research suggests that rasagiline might also have neuroprotective properties. This means it may help protect nerve cells from damage, potentially slowing the progression of Parkinson’s disease. However, more research is needed to confirm this effect[10].

Dosage and Administration

Rasagiline is typically taken orally (by mouth) once daily. The usual dosages are:

  • For early Parkinson’s disease: 1 mg once daily[1].
  • For advanced Parkinson’s disease (as an add-on to levodopa): 0.5 mg or 1 mg once daily[1][6].

It’s important to take rasagiline exactly as prescribed by your doctor. The medication can be taken with or without food[1].

Side Effects and Safety

Like all medications, rasagiline can cause side effects, although not everyone experiences them. Common side effects may include:

  • Headache
  • Joint pain
  • Indigestion
  • Depression
  • Flu-like symptoms

In some cases, rasagiline may cause more serious side effects. It’s important to inform your doctor immediately if you experience any unusual symptoms[1][4].

Rasagiline can interact with certain foods and medications. In particular, it’s important to avoid consuming large amounts of tyramine-rich foods (like aged cheeses and cured meats) while taking rasagiline. Always inform your healthcare provider about all medications and supplements you’re taking before starting rasagiline[1].

Ongoing Research

Researchers continue to study rasagiline to better understand its effects and explore its potential uses. Some areas of ongoing research include:

  • Long-term safety: Studies are being conducted to evaluate the long-term safety of rasagiline in patients with Parkinson’s disease[4].
  • Effects on sleep: Researchers are investigating how rasagiline might improve sleep disturbances in people with Parkinson’s disease[3].
  • Cognitive effects: Some studies are exploring whether rasagiline could help improve cognitive function in people with Parkinson’s disease[2].
  • Potential use in other conditions: Researchers are investigating whether rasagiline might be beneficial for other neurological conditions, such as ALS[10].
  • Early intervention: Some research is looking at whether rasagiline could be beneficial in the early stages of Parkinson’s disease, even before typical motor symptoms appear[5].

As with all medications, it’s important to discuss the potential benefits and risks of rasagiline with your healthcare provider. They can provide personalized advice based on your individual health situation and needs.

Aspect Details
Primary Uses Treatment of Parkinson’s disease, particularly for motor symptoms and wearing-off effects
Dosage Range 0.5 mg to 2 mg daily, with 1 mg being the most common dose
Key Benefits Improved motor function, reduced wearing-off symptoms, potential cognitive and sleep benefits
Study Populations Primarily Parkinson’s disease patients, some studies on healthy volunteers and other conditions (e.g., ALS)
Safety Profile Generally well-tolerated, with adverse events monitored in trials
Additional Investigations Effects on sleep, cognition, and potential neuroprotective properties
Measurement Tools UPDRS, MoCA, PDSS, WOQ-32, and various other scales for motor and non-motor symptoms
Trial Designs Randomized, placebo-controlled, double-blind studies; some open-label and observational studies

FAQ

  • What is rasagiline and how does it work? Rasagiline is a medication used to treat Parkinson's disease. It works by inhibiting an enzyme called monoamine oxidase B (MAO-B), which helps to increase dopamine levels in the brain. This can help improve motor symptoms associated with Parkinson's disease.
  • What are the main benefits of rasagiline observed in clinical trials? Clinical trials have shown that rasagiline can help improve motor symptoms, reduce wearing-off effects, and potentially have positive impacts on cognitive function and sleep disturbances in Parkinson's disease patients. Some studies have also explored its potential neuroprotective properties.
  • What dosages of rasagiline were typically used in clinical trials? Most clinical trials used dosages of 0.5 mg to 2 mg of rasagiline daily. The most common dosages were 1 mg once daily, though some studies explored the effects of 0.5 mg and 2 mg doses as well.
  • Were there any significant side effects reported in rasagiline clinical trials? While specific side effects varied between trials, rasagiline was generally well-tolerated. Researchers monitored for adverse events, which could include things like headaches, dizziness, or gastrointestinal issues. However, the full safety profile would need to be discussed with a healthcare provider.
  • Has rasagiline been studied for conditions other than Parkinson's disease? Yes, some clinical trials have explored rasagiline's potential in other conditions. For example, one study investigated its use in patients with amyotrophic lateral sclerosis (ALS) to assess its safety and potential neuroprotective effects in this population.

Ongoing Clinical Trials on Rasagiline

  • Study on Safinamide and Rasagiline for Treating Fatigue in Parkinson’s Disease Patients on Stable Dopaminergic Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Rasagiline: A medication used to treat Parkinson's disease that works by inhibiting the enzyme monoamine oxidase B (MAO-B), helping to increase dopamine levels in the brain.
  • Parkinson's Disease: A progressive neurodegenerative disorder that affects movement, balance, and coordination, characterized by symptoms such as tremors, stiffness, and difficulty with walking and balance.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, often used to evaluate the safety and effectiveness of new treatments or medications.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the actual medication being studied.
  • Wearing-off: A complication in Parkinson's disease where the effects of medication begin to wear off before the next dose is due, leading to a recurrence of symptoms.
  • Monoamine Oxidase B (MAO-B): An enzyme in the brain that breaks down dopamine; inhibiting this enzyme can help increase dopamine levels, which is beneficial in Parkinson's disease treatment.
  • Neuroprotective: Describing something that may protect nerve cells from damage or degeneration, potentially slowing the progression of neurological diseases.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body, which helps determine appropriate dosing and administration.
  • REM Sleep Behavior Disorder: A sleep disorder characterized by acting out vivid dreams during REM sleep, which can be an early sign of Parkinson's disease or other neurodegenerative conditions.
  • UPDRS (Unified Parkinson's Disease Rating Scale): A comprehensive assessment tool used to measure the severity and progression of Parkinson's disease symptoms across various domains.

References

  1. https://clinicaltrials.gov/study/NCT01879748
  2. https://clinicaltrials.gov/study/NCT01497652
  3. https://clinicaltrials.gov/study/NCT01032486
  4. https://clinicaltrials.gov/study/NCT03727139
  5. https://clinicaltrials.gov/study/NCT05611372
  6. https://clinicaltrials.gov/study/NCT02384512
  7. https://clinicaltrials.gov/study/NCT00203164
  8. https://clinicaltrials.gov/study/NCT00755027
  9. https://clinicaltrials.gov/study/NCT01232738
  10. https://clinicaltrials.gov/study/NCT01652313